Antibodies

CSL346 (anti-VEGFB) is an antibody targeting VEGFA.

CSL346 (anti-VEGFB) is an antibody targeting VEGFA.

CSL346 (anti-VEGFB) is an antibody targeting VEGFA.

Dupilumab is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Dupilumab is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Dupilumab is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Dupilumab is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Elotuzumab is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural

Enapotamab (anti-AXL) is an anti-AXL/UFO reference antibody. Enapotamab (anti-AXL) can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates.

Enapotamab (anti-AXL) is an anti-AXL/UFO reference antibody. Enapotamab (anti-AXL) can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates.

Enapotamab (anti-AXL) is an anti-AXL/UFO reference antibody. Enapotamab (anti-AXL) can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates.

Enapotamab (anti-AXL) is an anti-AXL/UFO reference antibody. Enapotamab (anti-AXL) can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates.